ArticlePublisher preview available

Treatment barriers in PANS/PANDAS: Observations from eleven health care provider families

Authors:
To read the full-text of this research, you can request a copy directly from the authors.

Abstract

Introduction: Pediatric acute-onset neuropsychiatric syndrome (PANS) and pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections (PANDAS) are severe but highly treatable postinfectious inflammatory brain conditions. Despite published diagnostic and treatment guidelines for this condition, there are long delays in obtaining appropriate care. The reasons for these delays are poorly understood. We sought to identify health care system barriers to timely treatment by examining cases of PANDAS/PANS occurring in children of health care professionals. Method: We recruited families via e-mail request through the PANDAS Physicians Network. Participating parents completed a structured questionnaire and provided a written case description. Results: Eleven families completed data collection, representing a broad spectrum of disease (child disease onset age 4-15, 7 males/4 females, mild to severe). Parents included 11 physicians, 2 mental health professionals, 2 nurses, and a PharmD. Nine cases (82%) had "very delayed" diagnosis and treatment (>4 weeks after onset). The most commonly encountered causes for treatment delay were clinician lack of awareness (82%), clinician skepticism (82%), overdependence on diagnostic testing (91%), and out-of-pocket expenses >$100 US (82%). Other common challenges included difficulties finding a provider to spearhead care (64%), psychological misdiagnosis (55%), and children's suppression of behaviors during assessments (55%). Conclusions: We found numerous barriers to treatment of PANDAS/PANS among children of health care providers. Our findings suggest that even among the medically sophisticated, PANDAS/PANS diagnosis and treatment remains challenging. Improvement in PANDAS/PANS education of clinicians who may encounter children with this disorder is 1 key step toward addressing our identified barriers. (PsycInfo Database Record (c) 2021 APA, all rights reserved).
Treatment Barriers in PANS/PANDAS: Observations From Eleven
Health Care Provider Families
Angela W. Tang, MD
1
, Heidi J. Appel, MD
2
, Stacie C. Bennett, MD
3
,
Leighann H. Forsyth, PhD
4
, Susan K. Glasser, MD
5
, Maura A. Jarka, RN, APN
6
,
Pierre D. Kory, MD
7
, Amy N. Malik, MD
8
, Andrea I. Martonoffy, MD
9
,
Lena K. Wahlin, MD
10
, Tricia T. Williams, MD
11
, Nate A. Woodin, LMFT
12
,
Lien C. Woodin, BSN
13
,IanK.T.Miller
14
, and Loren G. Miller, MD, MPH
15
1
Healthcare Partners Medical Group, Torrance, California, United States
2
Medstar Georgetown University Medical Center
3
Division of Neonatology, Children's Hospital of Oakland
4
Psychiatry, Case Western Reserve University
5
Department of Pediatrics, University of Connecticut
6
Cardiac Surgery Associates, Downers Grove, Illinois, United States
7
Aurora Health Care, Milwaukee, Wisconsin, United States
8
Division of Pulmonary and Critical Care Medicine, University of Wisconsin
9
Department of Family Medicine and Community Health, University of Wisconsin
10
Private Practice, Emergency and Intensive Care Medicine, Visby, Sweden
11
Endless Mountain Integrative Medicine, Troy, Pennsylvania, United States
12
Private Practice, Marriage and Family Therapy Portland, Maine, United States
13
Private Practice, Critical Care Nursing Portland, Maine, United States
14
Palos Verdes Peninsula High School, Rolling Hill Estates, California
15
Division of Infectious Diseases, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical
Center, Torrance, California
Introduction: Pediatric acute-onset neuropsychiatric syndrome (PANS) and pediatric
autoimmune neuropsychiatric disorder associated with streptococcal infections
(PANDAS) are severe but highly treatable postinfectious inammatory brain
conditions. Despite published diagnostic and treatment guidelines for this condition,
there are long delays in obtaining appropriate care. The reasons for these delays are
poorly understood. We sought to identify health care system barriers to timely
treatment by examining cases of PANDAS/PANS occurring in children of health care
professionals. Method: We recruited families via e-mail request through the PANDAS
Physicians Network. Participating parents completed a structured questionnaire and
provided a written case description. Results: Eleven families completed data
collection, representing a broad spectrum of disease (child disease onset age 415, 7
males/4 females, mild to severe). Parents included 11 physicians, 2 mental health
This article was published Online First October 7, 2021.
Tricia T. Williams, MD https://orcid.org/0000-0001-
5706-0897
Loren G. Miller, MD, MPH https://orcid.org/0000-
0003-0487-1711
None of the authors received any funding related to the
content of the manuscript.
Angela W. Tang and Loren G. Miller contributed to study
conception, data collection, data analysis, and manuscript
preparation. Ian K. T. Miller contributed to data analysis, and
manuscript preparation. The remaining authors contributed to
data collection, data analysis, and manuscript preparation.
Correspondence concerning this article should be
addressed to Loren G. Miller, MD, MPH, 1124 West
Carson Street, Box 466, Torrance, CA 90502, United
States. Email: lgmiller@ucla.edu
477
Families, Systems, & Health
©2021 American Psychological Association 2021, Vol. 39, No. 3, 477487
ISSN: 1939-0602 https://doi.org/10.1037/fsh0000602
This document is copyrighted by the AmericanPsychological Association or one of its allied publishers.
This article is intended solely for the personaluse of the individual user and is not to be disseminated broadly.
... Experiences of parents of children with PANS are unique due in part to sudden unexpected onset of symptoms, leaving little time for caregiver or child to develop positive coping strategies. Procuring knowledgeable practitioners for diagnosis and effective treatment often takes years, increasing caregiver stress O'Dor et al., 2022;Tang et al., 2021). ...
... Financial burdens abound as many seek providers beyond their region and insurance network. One large-scale study reported $4000 out-of-pocket expenses on average, and another reported expenses in the $100,000-$200,000 range (O'Dor et al., 2022;Tang et al., 2021). Calaprice et al. (2017) found more persistent PANS symptoms among those with access to care barriers including procuring a knowledgeable practitioner and ability to afford treatments (Calaprice et al., 2023). ...
... Inadequate access to quality care is a recurring issue in PANS literature, impacting the patient's symptoms as well as caregiver burden (Calaprice et al., 2023;Calaprice et al., 2017;O'Dor et al., 2022;Tang et al., 2021). With adequate access to care, caregiver burden has been found to decrease (Frankovich et al., 2018), whereas lack of access to care, including longer lag times from symptom onset to diagnosis, is associated with more severe PANS symptoms and greater persistence of symptoms (Calaprice et al., 2023). ...
Article
Objective: Children with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) experience sudden onset neuropsychiatric symptoms after infection or other triggers. Symptoms range from mild to severe, potentially lasting days, weeks, months, or longer. Exacerbation-related functional decline presents in many aspects of daily life, generally accompanied by family stress and caregiver burden. We sought to investigate the relationship between severity of PANS symptoms and caregiver burden/stress and the relationship between severity of PANS symptoms and degree of caregiver/child cohesion. Methods: This cross-sectional online study surveyed caregivers recruited from PANS-related social media support sites. The Pediatric Acute Neuropsychiatric Symptom Scale - Parent Version (PNSS) measured current severity. Caregiver Burden Inventory (CBI) and Caregiver Self-Assessment Questionnaire (CSAQ) assessed caregiver burden/stress. Inclusion of Other in the Self (IOS) scale determined caregiver-perceived current and desired cohesion with their child(ren) with PANS. Results: Of the 216 respondents 79.6% exceeded CBI threshold indicating need for respite in adult care receiver populations. On the CSAQ, 72.9% expressed high distress, 80.5% reported feeling overwhelmed, and 58.1% reported crying spells, meeting cutoffs for support/respite used in adult care receiver populations. Most caregivers reported not having the desired degree of cohesion with their child on the IOS (85.5%). Parents of children with more severe PNSS symptoms fared significantly worse on all measures (CBI: H = 57.83; CSAQ: F = 29.26; IOS: H = 38.04; p < 0.001 for all). Content analysis of comments revealed five themes: (1) severe caregiver and/or family emotional distress and trauma; (2) caregivers wondering what happened to their child; (3) lack of awareness and support among health and education professionals; (4) relationship strain with family, friends, and significant others; and (5) financial and/or legal struggles because of their child's diagnosis. Conclusion: There is strong need for support and respite for children with PANS and their families. Long-term effects including posttraumatic stress symptoms among family members should be studied.
... Barriers for the diagnosis and treatment of PANDAS/PANS include the lack of evidence on effective treatment options. The lack of clinicians familiar with PANDAS and PANS contributes to long distance travel (and associated travel expenses) for families seeking care (O'Dor et al., 2022;Tang et al., 2021). PANDAS/PANS symptoms overlap with symptoms of other conditions, thus the lack of a definitive test and reliance on a differential diagnosis can lead to delayed diagnosis. ...
... PANDAS/PANS symptoms overlap with symptoms of other conditions, thus the lack of a definitive test and reliance on a differential diagnosis can lead to delayed diagnosis. Misdiagnosis, and children's suppression of behaviors during assessments are also treatment barriers in PANDAS/PANS (O'Dor et al., 2022;Tang et al., 2021). Treatment for moderate-to-severe PANDAS/PANS generally requires pediatric specialists, and ideally, coordinated care among treating clinicians who may be in different care settings. ...
... o There are few clinicians with knowledge of how to diagnose or treat PANDAS/PANS, and the few clinics currently accepting PANDAS/PANS patients accept only a small (<10%) of patients (Tang et al., 2021). Moreover, PANDAS/PANS treatment often requires multidisciplinary teams and coordination of care given the complexity of the syndromes and the myriad symptoms. ...
Technical Report
Full-text available
The California Assembly Committee on Health has requested that the California Health Benefits Review Program (CHBRP)7 conduct an evidence-based assessment of the medical, financial, and public health impacts of AB 907, coverage of PANDAS and PANS, as amended on March 16, 2023.
... Conclusion: Many children who actually have PANS are misdiagnosed with CO-OCD (Johnson et al., 2021). Misdiagnosed children who are suffering from PANS may miss the opportunity for appropriate and effective treatment that, when delivered in a timely manner, could change the trajectory of their entire lives (Lotzin et al., 2021;Tang et al., 2021). It is therefore vitally important to provide in-depth education on PANS and CO-OCD to neuropsychologists and other care providers, especially in hospital settings. ...
Article
Full-text available
PANDAS is characterized by rapid onset of Obsessive Compulsive Disorder and/or tics following streptococcal infection in a previously healthy child. PANDAS is frequently misdiagnosed and misunderstood, which affects family quality of life (FQOL). A qualitative phenomenological design was used to examine FQOL in six families with a child with PANDAS. Data were collected through an audiotaped semi-structured interview and a phone interview to confirm findings. After rigorous data analysis, five themes emerged: Life Suddenly Turned Upside Down, My Child is Not Crazy, Emotional Distress within the Family, Major Life Alteration, and School Drastically Influences FQOL. Findings suggest that occupational performance and FQOL are severely restricted when a child has PANDAS. Implications for occupational therapy are discussed.
Article
Full-text available
Objectives Pediatric acute-onset neuropsychiatric syndrome (PANS) and its subset, pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS), are emerging autoimmune encephalopathies of childhood. Management guidelines are needed. This article, from the PANS/PANDAS Consortium, presents a consensus management guideline for the infection components. Accompanying papers from the Consortium discuss psychiatric and immunomodulatory management. Methods Literature was reviewed and integrated with the clinical experience of the authors to provide a set of practical guidelines. This article was submitted to all members of the PANS/PANDAS Consortium, and their additional comments were added. Results The relationships between PANS and infections are reviewed. An approach to the retrospective diagnosis of group A streptococcal infection for an operational definition of PANDAS is proposed. An initial course of anti-streptococcal treatment is proposed for all newly diagnosed PANS cases. Chronic secondary antimicrobial prophylaxis is suggested for children with PANDAS who have severe neuropsychiatric symptoms or recurrent group A Streptococcus-associated exacerbations. Guidelines for children with non-streptococcal PANS include vigilance for streptococcal pharyngitis or dermatitis in the patient and close contacts. All patients with PANS or PANDAS should also be closely monitored for other intercurrent infections, including sinusitis and influenza. Intercurrent infections should be diagnosed and treated promptly according to current standard guidelines. A guideline for the assessment of infection at initial onset or during neuropsychiatric exacerbations is also presented. Standard immunizations and attention to vitamin D are encouraged. Data indicating limited utility of adenotonsillectomy and probiotics are presented. Conclusion A working guideline for the management of infection issues in PANS and PANDAS, based on literature and expert opinion, is provided.
Article
Full-text available
Little is known about the natural history of children with pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections (PANDAS). This study prospectively followed 33 children with PANDAS for up to 4.8 years (mean 3.3 ± 0.7 years) after enrollment in a 24-week randomized, double-blind, placebo-controlled trial of intravenous immunoglobulin (IVIG) (N = 35). Fourteen of eighteen children randomized to placebo received open label IVIG 6 weeks after the blinded infusion, so follow-up results reported below largely reflect outcomes in a population of children who received at least one dose of IVIG. Telephone interviews with the parents of participants found that at the time of phone follow-up, 29 (88%) were not experiencing clinically significant obsessive–compulsive symptoms. During the interim period (6–57 months after entering the clinical trial), 24 (72%) had experienced at least one exacerbation of PANDAS symptoms, with a median of one exacerbation per child (range 1–12; interquartile range 0–3). A variety of treatment modalities, including antibiotics, IVIG, psychiatric medications, cognitive behavioral therapy, and others, were used to treat these exacerbations, and were often used in combination. The outcomes of this cohort are better than those previously reported for childhood-onset OCD, which may support conceptualization of PANDAS as a subacute illness similar to Sydenham chorea. However, some children developed a chronic course of illness, highlighting the need for research that identifies specific symptoms or biomarkers that can be used to predict the longitudinal course of symptoms in PANDAS.
Article
Full-text available
Objective: The goal of this study was to investigate treatment histories and outcomes in a large community sample of youth with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), and, where appropriate, to examine the impact of immune deficiency on treatment outcomes. Methods: A comprehensive internet-based survey was completed by parents or guardians of youth who had received physician diagnoses of PANS, or by young adults (age 18+) who had themselves been diagnosed by a physician (N = 698). Data regarding the treatment histories of these patients, including the variety of medical and psychological treatments employed and the caregiver- or self-reported response to each, are presented. Results: The PANS patients in this study had commonly been treated with antibiotic (N = 675), anti-inflammatory (N = 437), and/or psychotropic therapy (N = 378). Response to antibiotic treatment was best when treatment was relatively aggressive, with broad-spectrum antibiotics and courses of >30 days generally producing the best results (i.e., up to 52% of patients achieving a "very effective" response). For immune-deficient patients (caregiver-reported laboratory studies below normal limits; N = 108), use of broad-spectrum antibiotics appeared to be particularly desirable. Anti-inflammatory therapies, including over-the-counter medications such as ibuprofen, were at least "somewhat effective" for most patients. Intravenous immunoglobulin (IVIG) had been used to treat PANS in 193 (28%) of the patients and was at least "somewhat effective" for 89%, although for 18% of these, the effect was not sustained. The highest rate of sustained response to IVIG treatment was seen in immune-deficient patients who received doses of at least 0.8 g/kg IVIG on a regular basis. Psychotropic medications, most commonly SSRIs (38% reported a trial), were commonly employed, but were often ineffective (e.g., 44% found SSRIs "somewhat" to "very effective"). Many patients (N = 473) had received some form of psychotherapy with some benefit, with cognitive behavioral therapy found to be at least somewhat effective in a majority of those treated with this modality. Conclusion: Among the PANS patients represented in this study, relatively aggressive treatment courses targeted at eradicating infection and modulating the inflammatory response appeared to provide the best caregiver-reported therapeutic results, and to be generally well tolerated. Given its relative efficacy and tolerability, treatment targeting the inflammatory response may represent an underutilized approach in this population. The results of this study should be considered in light of the limitations inherent in a self-selected and administered online survey.
Article
Full-text available
Introduction Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) is a clinically heterogeneous disorder with a number of different etiologies and disease mechanisms. Inflammatory and postinfectious autoimmune presentations of PANS occur frequently, with some clinical series documenting immune abnormalities in 75%–80% of patients. Thus, comprehensive treatment protocols must include immunological interventions, but their use should be reserved only for PANS cases in which the symptoms represent underlying neuroinflammation or postinfectious autoimmunity, as seen in the PANDAS subgroup (Pediatric Autoimmune Neuropsychiatric Disorders associated with Streptococcal infections). Methods The PANS Research Consortium (PRC) immunomodulatory task force is comprised of immunologists, rheumatologists, neurologists, infectious disease experts, general pediatricians, psychiatrists, nurse practitioners, and basic scientists with expertise in neuroimmunology and PANS-related animal models. Preliminary treatment guidelines were created in the Spring of 2014 at the National Institute of Health and refined over the ensuing 2 years over conference calls and a shared web-based document. Seven pediatric mental health practitioners, with expertise in diagnosing and monitoring patients with PANS, were consulted to create categories in disease severity and critically review final recommendations. All authors played a role in creating these guidelines. The views of all authors were incorporated and all authors gave final approval of these guidelines. Results Separate guidelines were created for the use of immunomodulatory therapies in PANS patients with (1) mild, (2) moderate-to-severe, and (3) extreme/life-threatening severity. For mildly impairing PANS, the most appropriate therapy may be “tincture of time” combined with cognitive behavioral therapy and other supportive therapies. If symptoms persist, nonsteroidal anti-inflammatory drugs and/or short oral corticosteroid bursts are recommended. For moderate-to-severe PANS, oral or intravenous corticosteroids may be sufficient. However, intravenous immunoglobulin (IVIG) is often the preferred treatment for these patients by most PRC members. For more severe or chronic presentations, prolonged corticosteroid courses (with taper) or repeated high-dose corticosteroids may be indicated. For PANS with extreme and life-threatening impairment, therapeutic plasma exchange is the first-line therapy given either alone or in combination with IVIG, high-dose intravenous corticosteroids, and/or rituximab. Conclusions These recommendations will help guide the use of anti-inflammatory and immunomodulatory therapy in the treatment of PANS.
Article
Full-text available
Objective: This article outlines the consensus guidelines for symptomatic treatment for children with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) and Pediatric Autoimmune Neuropsychiatric Syndrome Associated with Streptococcal Infection (PANDAS). Methods: Extant literature on behavioral, psychotherapeutic, and psychopharmacologic treatments for PANS and PANDAS was reviewed. Members of the PANS Research Consortium pooled their clinical experiences to find agreement on treatment of PANS and PANDAS symptoms. Results: Current guidelines result from consensus among the Consortium members. Conclusion: While underlying infectious and inflammatory processes in PANS and PANDAS patients are treated, psychiatric and behavioral symptoms need simultaneous treatment to decrease suffering and improve adherence to therapeutic intervention. Psychological, behavioral, and psychopharmacologic interventions tailored to each child's presentation can provide symptom improvement and improve functioning during both the acute and chronic stages of illness. In general, typical evidence-based interventions are appropriate for the varied symptoms of PANS and PANDAS. Individual differences in expected response to psychotropic medication may require marked reduction of initial treatment dose. Antimicrobials and immunomodulatory therapies may be indicated, as discussed in Parts 2 and 3 of this guideline series.
Article
Objective: To describe the longitudinal association between disease severity, time established in clinical treatment, and caregiver burden in a community-based patient population diagnosed with pediatric acute-onset neuropsychiatric syndrome (PANS). Methods: The study included an observational longitudinal cohort design, with Caregiver Burden Inventories (CBIs) collected between April 2013 and November 2016 at the Stanford PANS multidisciplinary clinic. Inclusion criteria for this study were as follows: pediatric patients meeting strict PANS/pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) diagnostic criteria (n = 187), having a caregiver fill out at least 1 complete CBI during a disease flare (n = 114); and having family who lives locally (n = 97). For longitudinal analyses, only patients whose caregiver had filled out 2 or more CBIs (n = 94 with 892 CBIs) were included. In the study sample, most primary caregivers were mothers (69 [71.1%] of 97), the majority of PANS patients were male (58 [59.8%] of 97), and mean age at PANS onset was 8.8 years. Results: In a patient's first flare tracked by the clinic, 50% of caregivers exceeded the caregiver burden score threshold used to determine respite need in care receiver adult populations. Longitudinally, flares, compared with quiescence, predicted increases in mean CBI score (6.6 points; 95% CI, 5.1 to 8.0). Each year established in clinic predicted decreased CBI score (-3.5 points per year; 95% CI, -2.3 to -4.6). Also, shorter time between PANS onset and entry into the multidisciplinary clinic predicted greater improvement in mean CBI score over time (0.7 points per year squared; 95% CI, 0.1 to 1.3). Time between PANS onset and treatment with antibiotics or immunomodulation did not moderate the relationship between CBI score and time in clinic. Conclusions: PANS caregivers suffer high caregiver burden. Neuropsychiatric disease severity predicts increased caregiver burden. Caregiver burden tends to decrease over time in a group of patients undergoing clinical treatment at a specialty PANS clinic. This decrease could be independent of clinical treatment.
Article
Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcus, or PANDAS, is a syndrome of acute childhood onset of obsessive-compulsive disorder and other neuropsychiatric symptoms in the aftermath of an infection with Group A beta-hemolytic Streptococcus (GABHS). Its pathophysiology remains unclear. PANDAS has been proposed to result from cross-reactivity of antibodies raised against GABHS with brain antigens, but the targets of these antibodies are unclear and may be heterogeneous. We developed an in vivo assay in mice to characterize the cellular targets of antibodies in serum from individuals with PANDAS. We focus on striatal interneurons, which have been implicated in the pathogenesis of tic disorders. Sera from children with well-characterized PANDAS (n = 5) from a previously described clinical trial (NCT01281969), and matched controls, were infused into the striatum of mice; antibody binding to interneurons was characterized using immunofluorescence and confocal microscopy. Antibodies from children with PANDAS bound to ∼80% of cholinergic interneurons, significantly higher than the <50% binding seen with matched healthy controls. There was no elevated binding to two different populations of GABAergic interneurons (PV and nNOS-positive), confirming the specificity of this phenomenon. Elevated binding to cholinergic interneurons resolved in parallel with symptom improvement after treatment with intravenous immunoglobulin. Antibody-mediated dysregulation of striatal cholinergic interneurons may be a locus of pathology in PANDAS. Future clarification of the functional consequences of this specific binding may identify new opportunities for intervention in children with this condition.
Article
Objective: Pediatric acute-onset neuropsychiatric syndrome (PANS) includes pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and involves sudden-onset neuropsychiatric symptoms, including obsessions, compulsions, sensory difficulties, and dysgraphia after infection or other triggers. Our objective was to identify problems with areas of occupation, body functions, and performance skills during exacerbations. Method: In this online retrospective study, based on the Occupational Therapy Practice Framework: Domain and Process (2nd ed.), we surveyed parents of 111 children with PANS. Results: Activities of daily living, math, handwriting, extracurricular activities, free play, organized sports, community and family social participation, higher level thinking, attention, memory, sequencing, emotional coping, and energy and drive were commonly affected during exacerbations. During exacerbations, children often required assistance and adaptation to remain functional or were unable to function at a typical level. Conclusion: Children with PANS present with pervasive occupational performance needs during exacerbation. Children and families may benefit from accommodations to maximize function during this turbulent period.